Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 16;15(5):1012-1014.
doi: 10.1093/ckj/sfac047. eCollection 2022 May.

Sustained humoral response 6 months after the anti-SARS-CoV-2 mRNA-BNT162b2 vaccine in haemodialysis patients: should booster vaccine doses be given to all patients at the same time?

Vincenzo La Milia  1 , Silvia Tonolo  2 , Francesco Luzzaro  2 , Claudio Bonato  3 , Monica Limardo  1 , Selena Longhi  1 , Chiara Ravasi  1 , Sara Viganò  1 , Andrea Cavalli  1
Affiliations

Sustained humoral response 6 months after the anti-SARS-CoV-2 mRNA-BNT162b2 vaccine in haemodialysis patients: should booster vaccine doses be given to all patients at the same time?

Vincenzo La Milia et al. Clin Kidney J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Follow-up of IgG anti-SARS-CoV-2 (anti-spike S1 and S2) in patients who received a first vaccine dose (Month 1) and a second vaccine dose (Month 0). Blue indicates patients without seroconversion, red indicates patients with seroconversion and green indicates patients with seroconversion 6 months after the second dose vaccine administration and IgG anti-SARS-CoV-2 positive at administration of first vaccine dose. The curves are smooth cubic spline curves through the media of data. The dotted black line represents the threshold of positivity for IgG anti-SARS-CoV-2.
Figure 2:
Figure 2:
Trend of anti-SARS-CoV-2 IgG titre after the second vaccine dose administration. Linear regression and 95% confidence interval (shaded band). (A) All patients (r2 = 0.01); (B) patients without seroconversion 6 months after the second dose vaccine administration (r2 = 0.25); (C) patients with seroconversion 6 months after the second dose vaccine administration (r2 = 0.09); (D) patients with seroconversion 6 months after the second dose vaccine administration and IgG anti-SARS-CoV-2 positive at administration of first vaccine dose (r2 = 0.004). The dotted black line represents the threshold of positivity for IgG anti-SARS-CoV-2.
See this image and copyright information in PMC

References

    1. La Milia V, Tonolo S, Luzzaro Fet al. . The humoral immune response to SARS-CoV-2 mounts and is durable in symptomatic haemodialysis patients. Nephrol Dial Transplant 2021; 36: 1132–1134 - PMC - PubMed
    1. Carr EJ, Kronbichler A, Graham-Brown Met al. . Review of early immune response to SARS-CoV-2 vaccination among patients with CKD. Kidney Int Rep 2021; 6: 2292–2304 - PMC - PubMed
    1. Davidovic T, Schimpf J, Abbassi-Nik Aet al. . Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost. Kidney Int 2021; 100: 1334–1335 - PMC - PubMed
    1. Van Praet J, Reynders M, De Bacquer Det al. . Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: a multicenter observational study. J Am Soc Nephrol 2021;32: 3208–3220 - PMC - PubMed
    1. Strengert M, Becker M, Ramos GMet al. . Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. eBioMedicine 2021; 70: 103524. - PMC - PubMed